How ARBs Work: The Cardiologist's Guide to Angiotensin Receptor Blockers

Patients ask me about their blood pressure medications all the time, and the ARB class generates more questions than most. The names alone are a mouthful: losartan, valsartan, olmesartan, telmisartan, irbesartan, candesartan, azilsartan. You want to know what these drugs actually do, why I picked one for you instead of a different class, and whether the differences between them matter. This article is an honest explanation of how angiotensin receptor blockers work, why they earned a central place in modern cardiovascular care, and what I pay attention to when I prescribe them.

The System ARBs Are Designed to Block

Your body has an ancient hormone circuit that maintains your blood pressure and your salt-water balance. Cardiologists call it the renin-angiotensin-aldosterone system, or RAAS for short. It works like this. When your blood pressure drops or when your kidneys sense low salt, your kidneys release a chemical called renin. Renin starts a chain reaction that ends with the production of a hormone called angiotensin II. Angiotensin II is the workhorse of the system. It squeezes your blood vessels (raising blood pressure), tells your adrenal glands to retain salt and water (raising blood pressure further), makes you thirsty, and over time encourages your heart and blood vessels to thicken and stiffen.

In small amounts, all of that is helpful. It is what kept our ancestors alive when they lost blood from injury or got dehydrated on long walks. The problem is that for most modern people with high blood pressure, heart failure, or kidney disease, this system is on overdrive. It runs the blood pressure too high, makes the heart work too hard, and damages the kidneys over time.

Angiotensin II works by docking onto receptors on the surface of cells. The two main receptors are called AT1 and AT2. The AT1 receptor is the bad actor. It drives the constriction, the salt retention, the heart muscle thickening, and the scarring. The AT2 receptor does the opposite: when activated, it tends to dilate vessels and reduce inflammation. ARBs are designed to block the AT1 receptor selectively, leaving the AT2 receptor open. ACE inhibitors take a different route to the same effect: they block the enzyme that produces angiotensin II in the first place. Both classes lower the system's overall activity, with each class getting there through a different door.

What That Blockade Actually Does for You

When an ARB blocks the AT1 receptor in your blood vessels, the smooth muscle in those vessel walls relaxes. The vessels widen. Your blood pressure goes down. In your adrenal glands, less aldosterone gets made, so your kidneys hold on to less sodium and water. Your heart works against lower pressure, and over months and years a thickened heart muscle (a common consequence of long-standing high blood pressure) can remodel back toward normal. In your kidneys, ARBs relax a specific filtering vessel called the efferent arteriole. That relaxation lowers the pressure inside your kidney filters and protects them from the slow damage caused by high blood pressure and diabetes.

Those effects translate into a long list of clinical uses. ARBs are first-line therapy for high blood pressure. They are foundational treatment for heart failure with reduced ejection fraction, where today they are usually prescribed as part of the combination drug sacubitril-valsartan. They protect the kidneys in patients with diabetes and protein in the urine, in patients with chronic kidney disease, and after a kidney transplant. They are used after a heart attack in patients who cannot tolerate ACE inhibitors. They help prevent atrial fibrillation from coming back in patients with high blood pressure and an enlarged left atrium. They are standard treatment for the dilated aortas seen in Marfan syndrome and bicuspid aortic valve disease.

ARBs vs ACE Inhibitors: Which One Did I Pick and Why

If your last doctor had you on an ACE inhibitor like lisinopril and I switched you to an ARB, you probably want to know what changed. The honest answer is that for most patients the two classes are clinically equivalent on the outcomes that matter most.

The trial that settled this question was ONTARGET, published in the New England Journal of Medicine in 2008. It enrolled 25,620 high-risk vascular patients and randomized them to ramipril (an ACE inhibitor), telmisartan (an ARB), or both. After about 4.7 years of follow-up, the cardiovascular event rates were almost identical: 16.5 percent on ramipril, 16.7 percent on telmisartan, hazard ratio 1.01 with a confidence interval crossing 1. That trial is the basis for considering the two classes interchangeable in hard-endpoint terms. The combination arm did worse, with more low blood pressure, kidney injury, and high potassium without any improvement in outcomes. That finding is why I do not combine an ACE inhibitor with an ARB in the same patient.

The reason I usually pick one class over the other comes down to how well you tolerate it. ACE inhibitors cause a dry cough in about 4 to 20 percent of patients depending on how strict the definition. In ONTARGET, 4.2 percent of patients on ramipril developed a cough versus 1.1 percent on telmisartan. The cough comes from a separate molecule called bradykinin building up in the airways; ACE inhibitors block the breakdown of bradykinin as a side effect. ARBs do not interfere with bradykinin, so they cause next to no cough. Angioedema (sudden swelling of the lips, tongue, or throat) is rarer with both classes and is the more dangerous side effect, with a rate of about 0.3 percent on ramipril versus 0.1 percent on telmisartan in the same trial. For most patients I start with whichever class I think you will tolerate best, and I switch to an ARB if an ACE inhibitor produces a cough.

Differences Among the ARBs

Within the class, the drugs are more similar than different. There are a few differences worth knowing about.

Losartan is the oldest and the cheapest. It does not last quite as long in your bloodstream as the others, so I sometimes split it into a twice-daily dose when blood pressure is hard to control. The LIFE trial used losartan in patients with high blood pressure and a thickened left ventricle and showed it reduced strokes more than the older drug atenolol.

Valsartan has the largest evidence base in heart failure. It is the ARB component of sacubitril-valsartan, the combination drug that became standard of care for heart failure with reduced ejection fraction after the PARADIGM-HF trial showed it cut mortality compared with enalapril. If I think you may eventually need that combination, I often start with valsartan for that reason.

Telmisartan has the longest half-life in the class and a small bonus effect of helping the body use insulin a little better. I reach for it more in patients with metabolic syndrome.

Olmesartan and azilsartan are the most potent at lowering blood pressure on a milligram-for-milligram basis. They are the choice when blood pressure is stubborn.

Candesartan has the strongest evidence in heart failure with preserved ejection fraction from the CHARM trial program. Irbesartan has the strongest evidence for protecting kidneys from diabetic damage from the IDNT and IRMA-2 trials.

For most people with straight high blood pressure, any ARB will work. The choice depends on cost, on what other conditions you have, and on what evidence is strongest for your situation.

What I Watch When You Are on One

Two lab values matter when I start or increase the dose of an ARB: your serum creatinine (a measure of kidney function) and your potassium.

Creatinine often rises a little after starting an ARB. A bump of up to 30 percent is expected and acceptable. It happens from the way the drug relaxes that filtering vessel I mentioned earlier, which lowers the pressure inside your kidney filter. A bigger jump, or a creatinine that keeps climbing over weeks, suggests something else is going on. The most common explanations are dehydration, narrowed kidney arteries, or another drug interfering with kidney blood flow. If I see that, I investigate.

Potassium rises modestly on an ARB too. Suppressing aldosterone reduces how much potassium your kidneys excrete. In patients with advanced kidney disease, in patients on a potassium-sparing diuretic like spironolactone, or in patients taking potassium supplements, the potassium can climb to a dangerous level. I check labs within two weeks of starting or increasing an ARB and periodically thereafter.

For blood pressure itself, the goal in most current guidelines is below 130/80 mmHg. We use lower targets in patients with known cardiovascular disease, diabetes, or kidney disease. When the ARB alone does not get you there, I add a calcium channel blocker like amlodipine or a thiazide diuretic before going to other agents. That sequence comes from the ACCOMPLISH trial and the broader hypertension literature.

When ARBs Are Not the Right Choice

There are a few situations where I will not prescribe an ARB.

Pregnancy. ARBs cause severe damage to a developing fetus, including kidney failure and low amniotic fluid. Women of reproductive age on an ARB need reliable contraception. If you are planning a pregnancy or you become pregnant, tell me right away so we can switch you to a safer alternative like methyldopa or labetalol.

Severe narrowing of both kidney arteries (called bilateral renal artery stenosis). In those patients, the kidneys depend on angiotensin II's effect on the filtering vessels to maintain adequate filtration. Blocking it can cause sudden kidney failure. I screen for this in patients with sudden uncontrolled blood pressure or unexplained kidney function decline before starting an ARB.

A prior episode of angioedema on an ACE inhibitor. The cross-reactivity rate is low, around 3.5 percent in published data, and the consequences of airway swelling are severe enough that I usually pick a different class for those patients.

Severe high potassium at baseline. We treat the high potassium first, then revisit whether to start the ARB.

Where ARBs Fit in Modern Cardiovascular Care

Twenty years ago the debate around ARBs was whether they were as good as ACE inhibitors. That question is now settled in favor of "yes, equivalent for most outcomes." Current heart failure guidelines say "ACE inhibitor or ARB" rather than positioning one as superior. Both classes reduce death in heart failure with reduced ejection fraction by roughly 20 to 30 percent compared with placebo.

The more interesting story is what gets layered on top of an ARB in modern care. Sacubitril-valsartan adds a second mechanism (preservation of natriuretic peptides) and is the modern standard for heart failure. SGLT2 inhibitors like empagliflozin and dapagliflozin, added to background ARB therapy, produced further reductions in heart failure events and kidney disease progression in DAPA-HF, EMPEROR, DAPA-CKD, and EMPA-KIDNEY. Finerenone, a newer kidney-protective drug, layers on top of an ARB in diabetic kidney disease for still more benefit (FIDELIO-DKD and FIGARO-DKD trials). When a patient of mine is on an ARB plus an SGLT2 inhibitor plus a GLP-1 receptor agonist plus a statin, that is good care. Each drug targets a different pathway. Each one is proven. Together they protect the heart and kidneys far more than any single agent ever could.

What This Means for You

If your cardiologist has prescribed an ARB, you are on one of the most studied and safest classes of cardiovascular drugs in existence. Take it at the same time every day. Call us if you develop a bad cough, unusual swelling around the face or tongue, lightheadedness, or muscle weakness that might suggest a high potassium level. Do not stop the drug abruptly without talking to your clinician, especially if you have heart failure or kidney disease. Abrupt withdrawal can cause rebound problems.

If you are pregnant or trying to become pregnant, tell us immediately so we can move you to a pregnancy-safe alternative.

If you are deciding whether to start one in the first place, the evidence is clear. Patients who take their ARBs consistently have fewer heart attacks, fewer strokes, less progression of kidney disease, less heart failure, and fewer deaths. That is a medication worth taking.

Frequently Asked Questions

Can I drink alcohol on an ARB?

Moderate drinking is generally fine on an ARB. Heavy drinking can drop blood pressure too far when combined with the medication, and chronic heavy drinking raises blood pressure on its own and undermines the goal of treatment. Talk to me about your alcohol intake honestly so we can plan together.

Will I need to be on this for life?

For most patients, yes, especially if the indication is high blood pressure, heart failure, or kidney disease. Some patients with mild hypertension can come off the medication after real weight loss, sodium reduction, and improvement in their underlying drivers. I review medication need at every visit and reduce or stop drugs whenever the data support it.

Are generic ARBs as good as brand-name versions?

Yes. The generic versions of losartan, valsartan, olmesartan, and most others have the same active ingredient, the same dose, and the same effect as the brand-name original. Cost should not be a barrier to taking your medication.

I had a recall scare with my valsartan a few years back. Is the generic safe now?

The 2018 to 2019 recalls were caused by a contaminant called NDMA found in some generic valsartan, losartan, and irbesartan products from specific manufacturers. The FDA has worked with manufacturers to clean up those impurities, and generic ARBs sold in US pharmacies today have been re-approved. If you are worried about a specific lot, talk to your pharmacist.

What is the difference between an ACE inhibitor and an ARB if they both work on the same system?

ACE inhibitors block the production of angiotensin II. ARBs block angiotensin II from acting once it is produced. The end result is similar lowering of blood pressure and similar protection for the heart and kidneys. The main practical difference is tolerability: ACE inhibitors cause cough in a meaningful subset of patients and ARBs do not.

Can I take an ARB with my SGLT2 inhibitor and my GLP-1?

Yes, and in many of my patients with diabetes, kidney disease, or heart failure, that combination is exactly the right plan. Each drug protects the heart and kidneys through a different mechanism. Used together they produce more benefit than any single drug could on its own.

References

1. ONTARGET Investigators. "Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events." New England Journal of Medicine 358, no. 15 (2008): 1547-1559.

2. McMurray, John J. V., Milton Packer, Akshay S. Desai, et al. "Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF)." New England Journal of Medicine 371, no. 11 (2014): 993-1004.

3. Dahlöf, Björn, Richard B. Devereux, Sverre E. Kjeldsen, et al. "Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE)." Lancet 359, no. 9311 (2002): 995-1003.

4. Lewis, Edmund J., Lawrence G. Hunsicker, William R. Clarke, et al. "Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes (IDNT)." New England Journal of Medicine 345, no. 12 (2001): 851-860.

5. Pfeffer, Marc A., Karl Swedberg, Christopher B. Granger, et al. "Effects of Candesartan on Mortality and Morbidity in Patients with Chronic Heart Failure: The CHARM-Overall Programme." Lancet 362, no. 9386 (2003): 759-766.

6. Cohn, Jay N., and Gianni Tognoni. "A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure (Val-HeFT)." New England Journal of Medicine 345, no. 23 (2001): 1667-1675.

7. Jamerson, Kenneth, Michael A. Weber, George L. Bakris, et al. "Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients (ACCOMPLISH)." New England Journal of Medicine 359, no. 23 (2008): 2417-2428.

8. Whelton, Paul K., Robert M. Carey, Wilbert S. Aronow, et al. "2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults." Hypertension 71, no. 6 (2018): e13-e115.

9. Bakris, George L., Rajiv Agarwal, Stefan D. Anker, et al. "Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (FIDELIO-DKD)." New England Journal of Medicine 383, no. 23 (2020): 2219-2229.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.